The New England journal of medicine
-
Randomized Controlled Trial
Trial of Intravenous Immune Globulin in Dermatomyositis.
Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not been extensively evaluated. ⋯ In this 16-week trial involving adults with dermatomyositis, the percentage of patients with a response of at least minimal improvement based on a composite score of disease activity was significantly greater among those who received IVIG than among those who received placebo. IVIG was associated with adverse events, including thromboembolism. (Funded by Octapharma Pharmazeutika; ProDERM ClinicalTrials.gov number, NCT02728752.).
-
Comparative Study
A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
The safety and immunogenicity of the bivalent omicron-containing mRNA-1273.214 booster vaccine are not known. ⋯ The bivalent omicron-containing vaccine mRNA-1273.214 elicited neutralizing antibody responses against omicron that were superior to those with mRNA-1273, without evident safety concerns. (Funded by Moderna; ClinicalTrials.gov number, NCT04927065.).